Name: | enprofylline |
---|---|
PubChem Compound ID: | 1676 |
Molecular formula: | C8H10N4O2 |
Molecular weight: | 194.191 g/mol |
Synonyms: |
Enprofylline [USAN:INN]; EU-0100910; Lopac-P-5679; D04006; Enprofilina [INN-Spanish]; EINECS 255-201-8; 3-PROPYLXANTHINE; Enprofylline (USAN); Nilyph; 41078-02-8.
show more » |
Name: | enprofylline |
---|---|
Name (isomeric): | DB00824 |
Drug Type: | small molecule |
Synonyms: |
3-Propylxanthine; Enprofyllinum [INN-Latin]; 3-n-Propylxanthine; Enprofilina [INN-Spanish]
|
Brand: | Oxeze, Nilyph |
Category: | Antiarrhythmic Agents, Anti-Asthmatic Agents, Bronchodilator Agents |
CAS number: | 41078-02-8 |
Indication: | Used in the management of symptoms of asthma. Also used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. |
---|---|
Pharmacology: | Enprofylline is a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine. It antagonizes erythrocyte phosphodiesterase, increasing cAMP activity. |
Mechanism of Action: | Enprofylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, enprofylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. |
Absorption: | Rapidly absorbed from the digestive tract |
Protein binding: | 49% |
Half Life: | 1.9 hours |
Affected organisms: | Humans and other mammals |